The treatment of severe group a streptococcal infections

Current Infectious Disease Reports

Volumn 5, Issue 1, 2003, Pages 28-37

  Norrby Teglund, Anna ^a   Norrby, S Ragnar ^b   Low, Donald E ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTIBIOTIC AGENT; BACTERIAL TOXIN; BETA LACTAM ANTIBIOTIC; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; ERYTHROMYCIN; HYDROCORTISONE; IMMUNOGLOBULIN; INTERLEUKIN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PENICILLIN G; SUPERANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ANTIBIOTIC SENSITIVITY; BACTERIAL VIRULENCE; BACTERIUM ADHERENCE; CPG ISLAND; CYTOKINE PRODUCTION; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; EARLY DIAGNOSIS; HUMAN; MOLECULAR INTERACTION; MOLECULAR MECHANICS; MYOSITIS; NECROTIZING FASCIITIS; PATHOGENESIS; REVIEW; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; TOXIC SHOCK SYNDROME;

EID: 0012728485     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-003-0062-2     Document Type: Review

References (71)

1. Cone LA, Woodard DR, Schlievert PM, Tomory GS: Clinical and bacteriological observations of a toxic shock-like syndrome due to Streptococcus pyogenes. N Engl J Med 1987, 317:146-149.
2. Stevens DL: Invasive group A streptococcus infections. Clin Infect Dis 1992, 14:2-13.
3. The Working Group on Severe Streptococcal Infections: Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. JAMA 1993, 269:390-391.
4. Davies DH, McGeer A, Schwartz B, et al., and The Ontario group A streptococcal study group: Invasive group A streptococcal infections in Ontario, Canada. N Engl J Med 1996, 135:547-554.
5. Efstratiou A: Group A streptococci in the 1990s. J Antimicrob Chemother 2000, 45:3-12.
6. Chatellier S, Ihendyane N, Kansal RG, et al.: Genetic relatedness and superantigen expression of M type 1 group A streptococci isolates from severe and nonsevere invasive disease. Infect Immun 2000, 68:3523-3534.
7. Glauser MP: Pathophysiologic basis for sepsis: considerations for future strategies of intervention. Crit Care Med 2000, 28(Suppl 1):S4-S8.
8. Bone RC: The pathogenesis of sepsis. Ann Intern Med 1991, 115:457-469.
9. Okusawa S, Gelfand JA, Ikejima T, et al.: Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 1988, 81:1162-1172.
10. Tracey KJ, Beutler B, Lowry SF, et al.: Shock and tissue injury induced by recombinant human cachectin. Science 1986, 234:470-474.
11. Wang H, Bloom O, Zhang M, et al.: HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285:248-251.
12. Calandra T, Echtenacher B, Roy DL, et al.: Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 2000, 6:164-170.
13. Levi M, Ten Cate H: Disseminated intravascular coagulation. N Engl J Med 1999, 341:586-592.
14. Fisher CJJ, Yan SB: Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med 2000, 28 (Suppl):S49-S56.
15. Colman RW, Schmaier AH: Contact system: a vascular biology modulatory with anti-coagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 1997, 90:3819-3843.
16. Herwald H, Mörgelin M, Olsén A, et al.: Activation of the contact-phase system on bacterial surfaces - a clue to serious complications in infectious diseases. Nat Med 1998, 4:298-302.
17. Rasmussen M, Bjorck L: Proteolysis and its regulation at the surface of Streptococcus pyogenes. Mol Microbiol 2002, 43:537-544.
18. Fischetti VA: Streptococcal M protein: molecular design and biological behavior. Clin Microbiol Rev 1989, 2:285-314.
19. Boyle MD: Variation of multifunctional surface binding proteins-a virulence strategy for group A streptococci? J Theor Biol 1995, 21:415-426.
20. Sriskandan S, Cohen J: Gram-positive sepsis. Mechanisms and differences from gram-negative sepsis. Infect Dis Clin North Am 1999, 13:397-412.
21. Beutler B: Toll-like receptors: how they work and what they do. Curr Opin Hematol 2002, 9:2-10.
22. Kotb M: Bacterial pyrogenic exotoxins as superantigens. Clin Microbiol Rev 1995, 8:411-426.
23. Llewelyn M, Cohen J: Superantigens: microbial agents that corrupt immunity. Lancet Infect Dis 2002, 2:156-162.
24. Norrby-Teglund A, Kotb M: Host-microbe interactions in the pathogenesis of invasive group A streptococcal infections. J Med Microbiol 2000, 49:849-852.
25. Kotb M: Superantigens of gram-positive bacteria: structure-function analyses and their implications for biological activity. Curr Opin Microbiol 1998, 1:56-65.
26. Hemmi H, Takeuchi O, Kawai T, et al.: A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408:740-745.
27. Heeg K, Sparwasser T, Lipford GB, et al.: Bacterial DNA as an evolutionary conserved ligand signalling danger of infection to immune cells. Eur J Clin Microbiol Infect Dis 1998, 17:464-469.
28. Chatellier S, Kotb M: Preferential stimulation of human lymphocytes by oligodeoxynucleotides that copy DNA CpG motifs present in virulent genes of group A streptococci. Eur J Immunol 2000, 30:993-1001.
29. Hytönen J, Haataja S, Gerlach D, et al.: The SpeB virulence factor of Streptococcus pyogenes, a multifunctional secreted and cell surface molecule with strepadhesin, laminin-binding and cysteine protease activity. Mol Microbiol 2001, 39:512-519.
30. Hackett SP, Stevens DL: Streptococcal toxic shock syndrome: synthesis of tumor necrosis factor and interleukin-1 by monocytes stimulated with pyrogenic exotoxin A and streptolysin O. J Infect Dis 1992, 165:879-885.
31. Shanley TP, Schrier D, Kapur V, et al.: Streptococcal cysteine protease augments lung injury induced by products of group A streptococci. Infect Immun 1996, 64:870-877.
32. Muller MP, McGeer A, Low DE, and Ontario Group A Streptococcal Study: Successful outcome in six patients treated conservatively for suspected necrotizing fasciitis (NF) due to group A streptococccus (GAS) [abstract]. Paper presented at 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. December 16-19, 2001. Chicago.
33. Norrby SR: Side effects of cephalosporins. Drugs 1987, 34:105-120.
34. Stevens DL, Gibbons AE, Bergstrom R, Winn V: The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis 1988, 158:23-28.
35. Eagle H: Experimental approach to the problem of treatment failure with penicillin. I. Group A streptococcal infection in mice. Am J Med 1952, 13:389-399.
36. Stevens DL, Yan S, Bryant AE: Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect. J Infect Dis 1993, 167:1401-1405.
37. Mascini EM, Jansze M, Schouls LM, et al.: Penicillin and clindamycin differentially inhibit the production of pyrogenic exotoxins A and B by group A streptococci. Int J Antimicrob Agents 2001, 18:395-398.
38. De Azavedo JC, Yeung RH, Bast DJ, et al.: Prevalence and mechanisms of macrolide resistance in clinical isolates of group A streptococci from Ontario, Canada. Antimicrob Agents Chemother 1999, 43:2144-2147.
39. Descheemaeker P, Chapelle S, Lammens C, et al.: Macrolide resistance and erythromycin resistance determinants among Belgian Streptococcus pyogenes and Streptococcus pneumoniae isolates. J Antimicrob Chemother 2000, 45:167-173.
40. Savoia D, Avanmzini C, Bosio K, et al.: Macrolide resistance in group A Streptococci. J Antimicrob Chemother 2000, 45:41-47.
41. Aracil B, Minambres M, Oteo J, et al.: High prevalence of erythromycin-resistant and clindamycin-susceptible (M phenotype) viridans group streptococci from pharyngeal samples: a reservoir of mef genes in commensal bacteria. J Antimicrob Chemother 2001, 48:592-594.
42. Facinelli B, Spinaci C, Magi G, et al.: Association between erythromycin resistance and ability to enter human respiratory cells in group A streptococci. Lancet 2001, 358:30-33.
43. Abraham E: Why immunomodulatory therapies have not worked in sepsis. Intensive Care Med 1999, 25:556-566.
44. Schneider J, Voerman HJ: Abrupt hemodynamic improvement in late septic shock with physiological doses of glucocorticoids. Intensive Care Med 1991, 17:436-437.
45. Bollaert P, Charpentier C, Levy B, et al.: Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998, 26:645-650.
46. Briegel J, Kellermann W, Forst H, et al.: Low-dose hydrocortisone infusion attenuates the systemic inflammatory response syndrome. The Phospholipase A2 Study Group. Clin Invest 1994, 72:782-787.
47. Bernard GR, Vincent JL, Laterre PF, et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709.
48. Norrby-Teglund A, Stevens DL: Novel therapies in streptococcal toxic shock syndrome: attenuation of virulence factor expression and modulation of the host response. Curr Opin Infect Dis 1998, 11:285-291.
49. Ballow M: Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases. Allergy Clin Immunol 1997, 100:151-157.
50. Basma H, Norrby-Teglund A, McGeer A, et al.: Opsonic antibodies to the surface M protein, present in pooled normal immunoglobulins (IVIG), may contribute to its clinical efficacy in severe invasive group A streptococcal infections. Infect Immun 1998, 66:2279-2283.
51. Patel R, Rouse MS, Florez MV, et al.: Lack of benefit of intravenous immune globulin in a murine model of group A streptococcal necrotizing fasciitis. J Infect Dis 2000, 181:230-234.
52. Norrby-Teglund A, Kaul R, Low DE, et al.: Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production. J Immunol 1996, 156:3057-3064.
53. Norrby-Teglund A, Kaul R, Low DE, et al.: Evidence for the presence of streptococcal superantigen neutralizing antibodies in normal polyspecific IgG (IVIG). Infect Immun 1996, 64:5395-5398.
54. Lissner R, Struff WG, Autenrieth IB, et al.: Efficacy and potential clinical applications of Pentaglobin, an IgM-enriched immunoglobulin concentrate suitable for intravenous infusion. Eur J Surg 1999, 584(Suppl):17-25.
55. Stegmayr B, Bjorck S, Holm S, et al.: Septic shock induced by group A streptococcal infection: clinical and therapeutic aspects. Scand J Infect Dis 1992, 24:589-597.
56. Andersson U, Björck L, Skansén-Saphir U, Andersson J: Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev 1994, 139:21-43.
57. Kaul R, McGeer A, Norrby-Teglund A, et al., and The Canadian Streptococcal Study Group: Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome - a comparative observational study. Clin Infect Dis 1999, 28:800-807.
58. Arad G, Levy R, Hillman D, Kaempfer R: Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation. Nat Med 2000, 6:414-421.
59. Visvanathan K, Charles A, Bannan J, et al.: Inhibition of bacterial superantigens by peptides and antibodies. Infect Immun 2001, 69:875-884.
60. Ulrich RG, Olson MA, Bavari S: Development of engineered vaccines effective against structurally related bacterial superantigens. Vaccine 1998, 16:1857-1864.
61. Haywood CT, McGeer, Low DE: Clinical experience with 20 cases of group A streptococcus necrotizing fasciitis and myonecrosis: 1995 to 1997. Plast Reconstr Surg 1999, 103:1567-1573.
62. Kaul R, McGeer A, Low DE, et al., and the Ontario Group A Streptococcal Study Group: Population-based surveillance for group A streptococcal necrotizing fasciitis: clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Am J Med 1997, 103:18-24.
63. Lamothe F, D'Amico P, Ghosn P, et al.: Clinical usefulness of intravenous human immunoglobulins in invasive group A streptococcal disease: case report and review. J Clin Infect Dis 1995, 21:1469-1470.
64. Perez CM, Kubak BM, Cryer HG, et al.: Adjunctive treatment of streptococcal toxic shock syndrome with intravenous immunoglobulin:case report and review. Am J Med 1997, 102:111-113.
65. Cawley MJ, Briggs M, Haith LRJ, et al.: Intravenous immunoglobulin as adjunctive treatment for streptococcal toxic shock syndrome associated with necrotizing fasciitis: case report and review. Pharmacotherapy 1999, 19:1094-1098.
66. Yong JM: Necrotising fasciitis. Lancet 1994, 343:1427.
67. Mahieu LM, Holm SE, Goossens HJ, Van Acker KJ: Congenital streptococcal toxic shock syndrome with absence of antibodies against streptococcal pyrogenic exotoxins. J Pediatr 1995, 127:987-989.
68. Barry W, Hudgins L, Donta ST, Pesanti EL: Intravenous immunoglobulin therapy for toxic shock syndrome. JAMA 1992, 267:3315-3316.
69. Nadal D, Lauener RP, Braegger CP, et al.: T cell activation and cytokine release in streptococcal toxic shock-like syndrome. J Pediatr 1993, 122:727-729.
70. Chiu CH, Ou JT, Chang KS, Lin TY: Successful treatment of severe streptococcal toxic shock syndrome with a combination of intravenous immunoglobulin, dexamethasone and antibiotics. Infection 1997, 25:47-48.
71. Norrby-Teglund A, Norrby SR: Streptococcal toxic shock syndrome: modern therapy. In Infección 2002. Edited by Picazo JJ, Bouza E. Bilbao:Servisitem; 2002:221-242.